Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Examining Regional Brain Volume Differences in Radiologically Isolated Syndrome
Multiple Sclerosis
P15 - Poster Session 15 (5:30 PM-6:30 PM)
12-010

RIS occurs when asymptomatic white matter lesions are detected on MRI and present an opportunity to understand the earliest biological processes underlying MS onset. Existing studies have demonstrated that whole-brain and substructure volumes are lower in pwRIS vs. HCs, but the temporal sequence of atrophy, and what specific regions are preferentially affected are incompletely understood.

To evaluate regional brain volume differences using MRI in people with radiologically isolated syndrome(pwRIS) and healthy controls(HCs)

3T brain MRIs were acquired as part of the CanProCo study on 14 pwRIS(mean age: 50 years, 50% female) and 14 HCs(mean age: 40 years, 86% female) and processed using a voxel-based morphometry(VBM) pipeline. In each RIS subject, gray matter(GM) tissue class was extracted from T1-weighted MRI and co-registered and averaged to create an unbiased template.  Each subject was registered to the template and corrected for volume change due to this warping. Regional volumetric differences were assessed between RIS and HCs.  The MACruise brain parcellation pipeline was used to calculate brain parenchymal fraction(BPF), a measure of whole-brain atrophy.

Regions in the cerebellar hemispheric GM were smaller in RIS vs HCs(p<0.05).  These regions were concentrated along the lateral edges of the cerebellar hemispheres while sparing the vermis.  BPF was smaller (p<0.004), and the only other brain region demonstrating significant decrease in pwRIS vs. HCs was the right frontal medial cortex(p<0.05).

VBM analysis demonstrates that regions in the cerebellar hemispheric GM are preferentially atrophied in pwRIS vs. HCs.  These findings suggest that the cerebellum may be one of the initial regions affected in RIS and may be a major contributor to whole-brain atrophy observed in RIS. Longitudinal follow-up of this cohort will be informative to understand the temporal evolution of brain substructures affected as pwRIS develop symptoms consistent with MS, providing insight into the pathophysiology of early MS biological processes.

Authors/Disclosures
Jiwon Oh, MD, FAAN (St Michael's Hospital)
PRESENTER
Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.
No disclosure on file
Melanie Guenette No disclosure on file
No disclosure on file
Scott Patten, PhD (Univ of Calgary, Community Health Sciences) Dr. Patten has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Canadian Psychiatric Association. Dr. Patten has received publishing royalties from a publication relating to health care.
Alexandre Prat, MD (CHUM Hopital Norte Dame/ Dept of Neurology) The institution of Dr. Prat has received research support from CIHR and MSSC.
Roger Tam, PhD (University of British Columbia, MS/MRI Research Group) The institution of Dr. Tam has received research support from Natural Sciences and Engineering Research Council. The institution of Dr. Tam has received research support from Praxis Spinal Cord Institute.
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme.
Shannon Kolind, PhD, MSc, BSc (University of British Columbia) Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Kolind has received research support from Sanofi Genzyme. The institution of Dr. Kolind has received research support from Roche. The institution of Dr. Kolind has received research support from Biogen.